Interstitial Lung Disease
Acceleron Pharma Inc announced that Habib Dable, Acceleron’s President and Chief Executive Officer, will present a corporate overview during the 39th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 11 at 10:00 a.m. EST, in a virtual format.
A live webcast of the presentation will be accessible under “Events and Presentations” in the Investors & Media page of the Company's website at …
featured stories
View Conference Coverage
Take a look at some of our conference coverage, visit our roundup section.
Videos
-
Nov 19, 2020
Uncommon Interstitial Lung Diseases -- BAVLS
-
Nov 19, 2020
Interstitial Lung Disease with Dr. Sally Suliman
-
Nov 19, 2020
Emerging Therapies for Interstitial Lung Disease
Conference Roundup
- Jan 05, 2021
Acceleron to participate in the 39th Annual J.P. Morgan Healthcare Conference
Acceleron Pharma Inc announced that Habib Dable, Acceleron’s President and Chief Executive Officer, will present a corporate overview during the 39th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 11 at 10:00 a.m. EST, in a virtual format.
A…
Journal Scan
- Jan 04, 2021
Baseline pulmonary function tests help determine survival in ILD without pulmonary hypertension
Baseline pulmonary function tests may help determine mortality risk in patients with interstitial lung disease (ILD) without pulmonary hypertension (PH), according to a study.
In this study, 169 consecutive patients with ILD who underwent right heart catheterization were analyzed for…
Trending Topics
- Dec 07, 2020
First patient enrolled in phase 3 REBUILD study evaluating INOpulse for the treatment of fibrotic interstitial lung disease
Bellerophon Therapeutics, Inc, a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the first patient has been enrolled in its REBUILD Phase 3 registrational clinical study evaluating INOpulse®, a pulsed…
